IBSOR is committed to advancing precision oncology in Bangladesh through the integration of Next-Generation Sequencing (NGS) into its molecular diagnostics portfolio. As part of our long-term vision, we plan to establish comprehensive NGS-based cancer diagnostics to support clinicians with deeper genomic insights and personalized treatment strategies.

Key Focus Areas

• Targeted Gene Panels for Solid Tumors and Hematologic Malignancies We aim to launch validated gene panels that detect clinically actionable mutations in common cancers such as breast, lung, colorectal, prostate, and leukemia/lymphoma. These tests will support targeted therapy selection and prognosis
• Comprehensive Genomic Profiling (CGP) In collaboration with research and clinical partners, IBSOR will offer full exome or large-panel sequencing for advanced or treatment-resistant cancers, enabling identification of rare or novel driver mutations.
• Liquid Biopsy (ctDNA Analysis) Our future services will include circulating tumor DNA (ctDNA)-based assays for non-invasive cancer monitoring, minimal residual disease detection, and early relapse prediction.
• Hereditary Cancer Testing We plan to offer germline mutation analysis for hereditary cancer syndromes (e.g., BRCA1/2, Lynch syndrome) to support risk assessment, family screening, and preventive strategies.
• RNA Sequencing for Fusion Gene Detection Integrating RNA-seq assays for detecting gene fusions (e.g., ALK, ROS1, NTRK) and transcriptome-level expression analysis to guide targeted therapies and immunotherapies.
• Bioinformatics & Data Interpretation Support A dedicated bioinformatics pipeline will ensure accurate variant calling, annotation, and clinical reporting in compliance with international guidelines (e.g., AMP, ASCO, CAP).

As a forward-looking molecular and regenerative diagnostics center, IBSOR is actively planning to expand its Biologix division into next-generation cellular and regenerative therapies. Our future initiatives include:

Key Focus Areas

• Bone Marrow Concentrate (BMC): Introducing point-of-care preparation of bone marrow aspirates enriched with stem cells and growth factors to support orthopedic and regenerative applications.
• Mesenchymal Stem Cell (MSC) Therapy: Developing protocols for isolating, characterizing, and applying MSCs for use in inflammatory, orthopedic, and degenerative diseases.
• Induced Pluripotent Stem Cells (iPSCs): Establishing capabilities in iPSC reprogramming and differentiation for disease modeling, drug screening, and future personalized regenerative therapies.
• CAR-T Cell Research & Services: Exploring partnerships and capabilities in Chimeric Antigen Receptor T-cell therapy — a breakthrough immunotherapy for treating hematological malignancies and potentially solid tumors.

Through these advancements, IBSOR aims to position itself as a regional center of excellence for stem cell and cellular therapeutics, providing clinicians and researchers in Bangladesh access to cutting-edge biologic solutions aligned with international standards.

Key Focus Areas

• Antibiotic Sensivity.
• Bacterial Metagenomics.
• Viral Metagenomics.